**Table 3** ALPPS cases in patients with gallbladder cancer

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14-19 | 20 | 21-24 | 25 | 26 | 27 |
| Author | Knoefel | Knoefel | Kremer | Li | Li | Machado | Ratti | Schadde | Schadde | Schadde | Schadde | Schadde | Schnitzbauer | Schadde | Stockmann | Truant | Tsui | Tsui | Zhai |
| Ref | (16) | (16) | (17) | (18) | (18) | (19) | (20) | (21) | (21) | (21) | (21) | (21) | (2) | (22) | (23) | (24) | (25) | (25) | (26) |
| Year | 2015 | 2015 | 2015 | 2016 | 18 | 2017 | 2014 | 2015 | 2015 | 2015 | 2015 | 2015 | 2012 | 2014 | 2017 | 2015 | 2016 | 2016 | 2017 |
| Affiliation | Dusseldorf | Dusseldorf | Heidelberg | Hamburg | Hamburg | São Paulo | Milan | ALPPS Registry | ALPPS Registry | ALPPS Registry | ALPPS Registry | ALPPS Registry | Germany | ALPPS Registry | Berlin | France–Belgium | Hamburg | Hamburg | Heilongjiang |
| Country | Germany | Germany | Germany | Germany | Germany | Brazil | Italy | International | International | International | International | International | Multicentre | International | Germany | International | Germany | Germany | China |
| Study period | 2009–2011 | 2009–2011 | Sep 2011–Apr 2014 | May 2012–Mar 2014 | May 2012–Mar 2014 | Jul 2011–Jun 2016 | Jan 2012–Dec 2012 | Apr 2011–Jul 2014 | Apr 2011–Jul 2015 | Apr 2011–Jul 2016 | Apr 2011–Jul 2017 | Apr 2011–Jul 2018 | Sep 2007–Jan 2011 | 2010–2013 | 2011–2014 | Apr 2011–Sep 2013 | – | – | 2014 |
| N | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 6 | 1 | 4 | 1 | 1 | 1 |
| Age (yrs) | – | – | – | 48 | 52 |  | 72 | 77 | 72 | 31 | 61 | 70 | – | – | – | – | 70 | 57 | 46 |
| Sex (M:F) | – | – | – | F | F |  | F | – | – | – | – | – | – | – | – | – | F | F | M |
| Tumor size | – | – | – | 8 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Number of lesions | – | – | – | 1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | Multiple |
| Primary lesion location | – | – | – | Right lobe-S4 | Right lobe-S5 | – | – | – | – | – | – | – | – | – | – | – | – | – | S5-S8-S4 |
| Neoadjuvant treatment | – | – | No | No | Gemcitabine-cisplatin | – | No | – | – | – | – | – | – | – | – | – | No | Yes | No |
| Type of liver resection |  |  | – | Right trisectionectomy (hybrid) | Right trisectionectomy (hybrid) | – | Right trisectionectomy + biliary confluence resection | – | Right trisectionectomy | – | – | – | – | – | – | – | DALPPS | DALPPS |  |
| MILS |  |  | – | No | No | – | No | – | – | – | – | – | – | – | – | – | – | – | No |
| Days 1–2 stage |  |  | – | 10 | 15 | – | 6 | – | – | – | – | – | – | – | – | – | 7 | 9 | 8 |
| FLR pre1 |  |  | – | 491 mL | 329 mL | – | – | – | – | – | – | – | – | – | – | – | 387 mL | 668 mL | 461 mL |
| FLR post1 |  |  | – | 911 mL | 544 mL | – | – | – | 26% | – | – | – | – | – | – | – | 667 mL | 1,031 mL | 1,001 mL |
| FLR hypertrophy |  |  | – | 85% | 65% | – | 29% | – | – | – | – | – | – | – | – | – | 73% | 55% | 117% |
| CD post-2 |  |  | – | IIIa | I | – | 5 | V (septic shock) | V (septic shock) | V (septic shock) | V (septic shock) | V (septic shock) | – | – | – | – | 0 | V (ARDS) | – |
| LOS post-2 |  |  | – | 34 | 21 | – | 3 | – | – | – | – | – | – | – | – | – | 13 | 30 | – |
| 30-day mortality |  |  | – | No | – | – | Yes | – | – | – | – | – | – | – | – | – | No | Yes | – |
| Adjouvant treatment |  |  | – | No | – | – | No | – | – | – | – | – | – | – | – | – | – | – | – |
| Overall survival |  |  | – | Alive (6 months) | – | – | Death (3 days) | Death <90 days | Death <90 days | Death <90 days | Death <90 days | Death <90 days | – | 2–6 <90 days | – | – | – | Death (1 month) | Alive (23 months) |
| Recurrence |  |  | Yes (3.5 mo) | No | – | – | No | No | No | No | No | No | – | – | – | – | No | – | No |